Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | KCNJ6 | P48051 | 1/20 | 0.42 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.42 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | FPR1 | P21462 | 1/20 | 0.38 |
| ▸ | FPR2 | P25090 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1612083 | 0.87 | THRB (0.42) | SMN1; SMN2HTTPKMTP53MAPT | |
| SCHEMBL1612005 | 0.86 | SMN1; SMN2 (0.46) | SMN1; SMN2MEN1KMT2AKCNJ6KCNJ5 | |
| SCHEMBL1493570 | 0.84 | TP53 (0.38) | SMN1; SMN2HTTPKMTP53MAPT | |
| SCHEMBL1493574 | 0.79 | TP53 (0.41) | SMN1; SMN2HTTPKMTP53MAPT | |
| SCHEMBL1612000 | 0.77 | HTT (0.45) | SMN1; SMN2HTTTP53MAPTALDH1A1 | |
| SCHEMBL1493469 | 0.77 | MAPT (0.44) | SMN1; SMN2KMT2AHTTPKMTP53 | |
| SCHEMBL1493414 | 0.74 | HSD11B1 (0.45) | SMN1; SMN2MEN1KMT2AHTTPKM | |
| SCHEMBL1612525 | 0.73 | ALDH1A1 (0.52) | MEN1KMT2AHTTMAPTALDH1A1 | |
| SCHEMBL1493380 | 0.72 | MAPT (0.45) | MEN1KMT2AHTTTP53MAPT | |
| SCHEMBL1493310 | 0.71 | ALDH1A1 (0.42) | SMN1; SMN2HTTTP53MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110086889-A1 | TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-04-14 | — | — | US | claimed |
| US-20110086889-A1 | TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086889-A1 | TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY1R | SMN1; SMN2 4215/4885MEN1 683/4885KMT2A 1510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.